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The combined clinical and pathophysiologic characteristics 
and diagnostic features as well as current concepts of 
pathogenesis, therapy and prevention of the principal 
forms of cardiomyopathy are reviewed. These include 
hypertrophic cardiomyopathy, dilated cardiomyopathy, re- 
strictive cardiomyopathy and specific cardiac muscle dis- 
ease. Emphasis is placed on recent developments and 
unresolved questions requiring application of newer tech- 
niques of molecular biology and genetics and adult myocyte 
culturing. 
(,I Am Co11 Cardiol 1989;13:1219-39) 
“D’oti venons nous? Que sommes nous? Oti allons nous?” inent as causes of morbidity, disability and mortality. This 
Thus, Paul Gauguin entitled his monumental canvas of observation holds for a wide range of presentations and 
1897, which addresses the human condition and life manifestations, such as decreased tolerance of activity, 
cycle. Since then, biomedical science has elucidated much congestive 
of this cycle and also has prolonged it for 
many individuals. If we look at the natural 
history of individual diseases, the same may 
be said for many diseases of heart muscle. 
We know a great deal more about their origins 
and are able to recognize them earlier and 
more widely. Their life cycle has been extended. 
and we see the late stages with increasing fre- 
quency. 
Some afflictions of the heart have decreased 




heart failure, arrhythmias, conduction distur- 
bances. chest pain and sudden death. 
This article will not review present knowl- 
edge and understanding of the cardiomyopathies 
in detail; many recent comprehensive reviews 
are available (l-12). Rather, we shall emphasize 
recent contributions, try to present the high- 
lights of our knowledge in perspective, ad- 
dress gaps of knowledge and understand- 
ing and raise questions to be addressed in the 
future. 
in prevalence and importance. at least in the more developed 
countries, partly because of effective prevention or treat- 
ment, or both, and partly for reasons that are unclear. 
Among these are syphilis, rheumatic fever, tuberculosis 
and malignant hypertension. On the other hand, diseases of 
heart muscle appear to be more prevalent either because 
they have increased in incidence or because they are being 
recognized more frequently; they have become more prom- 
Historical Perspective 
Disease of heart muscle. as distinct from valvular, coro- 
nary, pericardial or congenital heart disease, was recognized 
as early as 1891 by Krehl(13) in Germany, and reemphasized 
in 1901 by Josserand and Gallavardin (14) in France and in 
From the Cardiovascular Division, Department of Medicine, Charles A. 
Dana Research Institute and the Harvard-Thorndike Laboratory of Beth 
Israel Hospital. Beth Israel Hospital and the Harvard Medical School, 
Boston, Massachusetts. Dr. Lorell is supported by an Established Investiga- 
torship of the American Heart Association, Dallas, Texas. 
Address for reorints: Walter H. Abelmann. MD, Cardiovascular Division. 
Beth Israel Hospital. 330 Brookline Avenue. Boston, Massachusetts 02215. 
This article is port of u series of articles celebrating the 
40th anniversury of the American College of Cardiology. 
The series crttempts to set the stage for the future by 
describing current stute of the urt munagemcnt of selected 
major curdiovascular problems and the basic knowledge 
thut Mill provide directions for rrdvances in diagnosis and 
therupy. 
cl989 by the American C‘ollcge of Cadiology l17~5-lO97!89/S3.50 
1220 ABELMANN AND LORELL JACC Vol. 13, No. 6 
CHALLENGE OF CARDIOMYOPATHY May 1989:1219-39 
1933 by Christian (15) in the United States. However, it 
came into prominence and wide recognition only in the 
second half of this century, thanks largely to the contribu- 
tions by Mattingly (16), who reintroduced the term “primary 
myocardial disease,” and Harvey et al. (17) in the United 
States, and by Brigden (18), who introduced the term car- 
diomyopathy, and Goodwin and associates (19) in Great 
Britain. Originally, the designation “primary” signified that 
the disease predominantly affected the myocardium. Later, 
“primary” came to designate idiopathic afflictions of heart 
muscle, as distinguished from diseases of other organ sys- 
tems that affect the heart secondarily. 
Classification of cardiomyopathy. Initially, primary myo- 
cardial disease was considered a diagnosis of exclusion, that 
is, a diagnosis to be made after other etiologies had been 
ruled out. Gradually, it became recognized that there were 
characteristic albeit nonspecific features that permitted rec- 
ognition of primary myocardial disease on its own merits. 
Furthermore, it became evident that there were different 
groupings of structural and physiologic characteristics, lead- 
ing to a functional classification first introduced by Goodwin 
(19) and, in 1968, adopted by the World Health Organization 
(WHO) (20). This classification distinguished hypertrophic 
cardiomyopathy with or without obstruction, initially known 
in the United States as idiopathic hypertrophic subaortic 
stenosis (IHSS), from congestive cardiomyopathy and re- 
strictive cardiomyopathy. In a later modification, the WHO 
(21) classification was altered in that “congestive cardiomy- 
opathy” was relabeled “dilated cardiomyopathy”, and 
cases in which a specific etiology or associated systemic 
disease could be identified were now assigned to a new 
category of “specific heart muscle disease.” Furthermore, 
two new categories, “obliterative cardiomyopathy” and 
“indeterminate cardiomyopathy” were added. 
Heart muscle disease secondary to specific causes or 
disease entities (for example, thiamine deficiency, hemo- 
chromatosis, amyloidosis, muscular dystrophy) according to 
the WHO definition are no longer included among the 
cardiomyopathies. However, the similar clinical presenta- 
tions and therapeutic problems have led to widespread 
continuation of the use of the term cardiomyopathy for such 
cases, especially the frequently encountered entity of con- 
gestive heart failure secondary to chronic ischemic heart 
disease, generally referred to as “ischemic cardiomyopa- 
thy.” The pragmatic advantage to the clinician of continuing 
to include congestive heart failure associated with specific 
heart muscle disease under the concept of dilated cardiomy- 
opathy has been previously discussed in detail (5). 
Pathogenetic mechanisms. The original concept that most 
idiopathic cardiomyopathies were attributable to a specific 
cause, if one but searched long enough and awaited the 
results of further research, has had to be discarded. More 
than 75 specific heart muscle diseases that may manifest as 
dilated cardiomyopathy have been described (5,22), but 
these disorders share common clinical, functional and patho- 
logic manifestations. Moreover, experimental models of 
heart failure have shown a good deal of communality and 
overlap in the characteristics of individual forms of cardio- 
myopathy or specific heart muscle disease. Therefore, the 
concept of cardiomyopathy as a pluricausal or multifactorial 
disease has gained increasing acceptance (2,5,23). The prin- 
cipal pathogenetic mechanisms under current consideration 
include genetic factors, metabolic disturbances, hormonal 
imbalances, toxins, calcium overload, altered vascular reac- 
tivity, hypoxia, free radicals, infection and immunelautoim- 
mune processes. 
Incidence and Prevalence of Cardiomyopathy 
In developed countries, the annual incidence of cardio- 
myopathy ranges from 0.7 to 7.5 cases per 100,000 popula- 
tion (24), and the prevalence in England has been reported as 
8,317 cases per 100,000 population (25). At least 0.7% of 
cardiac deaths in the United States have been attributed to 
cardiomyopathy (24); the male cardiomyopathy mortality is 
twice that of female, and blacks have more than twice the 
mortality rate of whites. It is generally believed that dilated 
cardiomyopathy constitutes >90% of all cardiomyopathies 
encountered. 
In less developed countries, especially in the tropics, 
cardiomyopathies are most prevalent and also constitute a 
greater if not dominant fraction of heart disease (24). This 
greater prevalence is largely in the form of dilated cardio- 
myopathy and to some extent of restrictive cardiomyopathy; 
it has been attributed variously to genetic factors, nutritional 
deficiency, infection including Chagas’ disease, physical 
stress, untreated hypertension, endomyocardial fibrosis and 
toxins such as ethanol (26). 
Hypertrophic Cardiomyopathy 
Hypertrophic cardiomyopathy has held the fascination of 
cardiologists despite its rarity because of its dramatic aber- 
rations of geometry and function and its importance as a 
cause of disability and death in young, otherwise healthy 
adults. Over the past 3 decades, our appreciation of the 
pleomorphic, geometric and hemodynamic manifestations of 
hypertrophic cardiomyopathy has greatly increased because 
of an enlarging body of natural history data and technologic 
advances in cardiac imaging. However, major gaps in knowl- 
edge of the etiology and pathophysiology remain. This 
discussion will first present the historical perspective of the 
initial disparate evolution and more recent convergence of 
concepts regarding pathogenic mechanisms in hypertrophic 
cardiomyopathy. From this perspective, we will highlight 
major unanswered issues that require attention if further 
strides are to be made in the treatment of symptomatic 
patients, prevention of premature sudden death and, ulti- 
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mately, alteration of natural history and the regression of 
hypertrophy in this cardiomyopathy. 
Historical Perspective 
Early studies. Hypertrophic cardiomyopathy has been 
recognized in clinical practice for only 3 decades. However, 
Brigden (27) recently emphasized that isolated cardiac hy- 
pertrophy with an element of outflow tract stenosis was 
identified by pathologists in the 19th century and clearly 
described by Schminke as “Muskuliise Conusstenosen” in 
1907. Both its familial nature and association with sudden 
death were raised by Evans’ description (28) of a kindred 
with unexplained hypertrophy in 1949. However, this disor- 
der first came to widespread international attention as an 
entity that could mimic valvular stenosis due to functional 
obstruction by hypertrophied muscle with the publication of 
Brock’s case report (29) in 1957 and Teare’s description (30) 
in 1958 of the necropsy finding of unexplained septal hyper- 
trophy in seven young adult victims of sudden death. During 
the 196Os, investigators in the United States, particularly at 
the National Institutes of Health, focused on the identifica- 
tion and detailed assessment of those patients with the 
obstructive form of the disease. In addition to confirming the 
familial transmission of this entity, elegant hemodynamic 
studies elucidated the physiology of this subset of patients 
whose hallmark was the presence of a dynamic systolic 
murmur and pressure gradient consistent with the presence 
of functional obstruction to left ventricular outflow (31,32). 
The anatomic basis of the dynamic outflow gradient was 
suggested by angiographic studies and shown by M-mode 
and later two-dimensional echocardiography to depend on 
narrowing of the left ventricular outflow tract by asymmetric 
septal hypertrophy and systolic anterior movement and 
apposition of the mitral valve leaflet to the septum (33). 
This concept of hypertrophic cardiomyopathy as a disor- 
der whose fundamental characteristics were the presence of 
asymmetric septal hypertrophy and dynamic outflow tract 
obstruction was supported by the clinical improvement of 
symptomatic patients with interventions aimed at reducing 
the dynamic outflow gradient, including the use of negative 
inotropic agents such as propranolol and surgical ablation of 
the gradient using the myotomy-myectomy procedure pio- 
neered by Morrow et al. (34). Necropsy studies in these 
patients demonstrated the consistent finding of disorganiza- 
tion and malalignment of the myofibrils (myofibrillar disar- 
ray). which is not unique to hypertrophic cardiomyopathy 
but is clearly more extensive in this disorder than in second- 
ary hypertrophy from pressure overload or congenital heart 
disorders (35). 
Obstructive versus nonobstructive form. During this ex- 
citing period of discovery and description, it was clearly 
recognized that not all patients had severe outflow tract 
pressure gradients and that abnormalities of diastolic func- 
tion were common (36). Nonetheless, the emphasis on 
regional septal hypertrophy and its relation to the systolic 
murmur and gradient led to a profusion of terms such as 
“idiopathic hypertrophic subaortic stenosis” and “muscular 
subaortic stenosis.” Furthermore, particularly in the United 
States, the widespread interest in the subset of patients with 
“IHSS” was accompanied by their ease of recognition by 
physical examination and office-based echocardiography. It 
can be argued that these combined factors resulted in the 
widespread perception that hypertrophic cardiomyopathy 
could only be identified in patients with the clinical signs of 
rest or provokable outflow tract gradients who had docu- 
mented asymmetric septal hypertrophy and systolic anterior 
mitral valve motion. As a consequence, during the “IHSS” 
era, patients with other phenotypic manifestations, nonob- 
structive physiology and older patients with the confounding 
presence of mild hypertension were outside the mainstream 
of clinical recognition and study. 
Clinical investigations. In parallel with these lines of 
investigation. there was the acquisition of natural history 
data, identification of kindreds and clinical investigation of 
patients with hypertrophic cardiomyopathy drawn from 
somewhat different patient referral populations in the United 
Kingdom. These observations led to the insights that the 
presence of a systolic murmur indicative of a left ventricular 
outflow gradient was not an invariable feature of the disease 
within kinships of patients, or in the natural history of an 
individual followed from adolescence through adulthood 
(2.37,38). In individuals who presented with the dramatic 
signs of outflow obstruction in young adulthood, clinical 
deterioration in middle age was frequently associated with 
the disappearance of the dynamic systolic murmur and the 
development of physiologic features resembling those of 
restrictive cardiomyopathy. Second, it became apparent 
that. although the extent of septal hypertrophy and duration 
of mitral leaflet-septal apposition correlate well with the 
magnitude of the systolic gradient, cardiac morphology does 
not correlate well with either symptoms or natural history. 
Severe symptoms of angina, pulmonary congestion and 
syncope occur in patients with either the obstructive or the 
nonobstructive forms of the disease, and many but not all 
investigators observed that there appears to be little relation 
between the magnitude of the systolic gradient and the 
severity of symptoms or improvement in functional status 
with pharmacologic agents (39-41). 
Echocardiographic contributions to diagnosis of morpho- 
logic forms. Two-dimensional cineangiographic studies and 
the ability to look at cardiac geometry in a new way with 
two-dimensional echocardiography revealed that patients 
with hypertrophic cardiomyopathy can exhibit unexplained 
hypertrophy in regions other than the upper portion of the 
ventricular septum, including the midportion of the left 
ventricle. the apex, the lower portion of the septum as well 
as severe concentric hypertrophy (42-44). Furthermore, this 
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variability in cardiac geometry can occur not only in isolated 
individual patients but also within kindreds (45). Two mor- 
phologic forms of hypertrophic cardiomyopathy merit par- 
ticular attention: apical hypertrophy and midventricular 
hypertrophy. These atypical forms are of interest not be- 
cause of their prevalence but because they underscore the 
fact that our perception of hypertrophic cardiomyopathy 
has been powerfully shaped by the capabilities and limita- 
tions of the tools available for the study of patients. Both of 
these forms of hypertrophic cardiomyopathy are associated 
with nonspecific physical findings, escape detection by M- 
mode echocardiography and have come to attention with 
two-dimensional imaging with use of either contrast ventric- 
ulography or two-dimensional echocardiography. 
In the late 1970s Japanese investigators reported on 
cohorts of patients with severe apical hypertrophy identified 
by invasive contrast ventriculography who lacked signs of 
outflow tract obstruction and often came to clinical attention 
because of bizarre electrocardiographic (ECG) findings of 
severe left ventricular hypertrophy with giant negative T 
waves (46). This expression of hypertrophic cardiomyopathy 
is especially prevalent in Japan but has now been identified 
with use of two-dimensional echocardiography in other 
genetic and geographic populations and within kindreds with 
other phenotypic patterns of hypertrophy. A second subset 
of patients that did not receive attention in the era of the 
identification of hypertrophic cardiomyopathy with M-mode 
echocardiography is that of patients with severe midventric- 
ular hypertrophy below the level of the outflow tract at the 
level of the papillary muscles. At cardiac catheterization, 
such patients can be shown to have midventricular “ob- 
struction” with a gradient between the left ventricular apical 
region and the remainder of the chamber due to the genera- 
tion of markedly elevated levels of left ventricular systolic 
pressure by an isometric contraction in a discrete apical 
cavity (42,47). In our experience and that of Wigle et al. (42) 
some patients show progression to an appearance of a 
noncontractile apical aneurysm and apical thrombus forma- 
tion can occur. In such patients who have documentation of 
normal epicardial coronary arteries, the responsible mecha- 
nism may be the repetitive generation of high levels of 
isometric pressure, which ultimately results in episodes of 
ischemic injury and necrosis. 
The true frequency of these different phenotypes of 
hypertrophic cardiomyopathy is difficult to ascertain. Refer- 
ral centers with expertise in the medical and surgical man- 
agement of the obstructive form of the disease report a 
predominance of asymmetric septal hypertrophy, whereas 
this morphologic expression appears to occur in the minority 
at centers that accrue a different spectrum of patients. 
Nonetheless, these lines of investigation and observation 
from different referral populations and different parts of the 
world have converged to a consensus position that the 
central morphologic feature of hypertrophic cardiomyopathy 
is the presence of a nondilated hypertrophied left ventricle 
detected in the absence of a primary illness that could cause 
hypertrophy (48,49). 
Evolving Concepts and New Questions: Role 
of Ischemia 
Myocardial ischemia. The importance of ischemia in hy- 
pertrophic cardiomyopathy is an area of increasing interest 
and clinical investigation. Angina pectoris is a cardinal 
symptom of hypertrophic cardiomyopathy and can occur in 
all morphologic forms of the disease. There is substantial 
evidence that the symptom of angina pectoris is related to 
myocardial ischemia in these patients. Similar to observa- 
tions in patients with secondary pressure overload hypertro- 
phy (50), interventions such as pacing tachycardia and 
exercise can provoke chest pain in association with elevation 
of left ventricular filling pressure, myocardial lactate produc- 
tion and the development of reversible perfusion defects 
detectable by thallium imaging (51-53). In addition, autopsy 
studies of patients with hypertrophic cardiomyopathy and 
patent epicardial coronary arteries have demonstrated the 
presence of fibrous tissue that varies from a patchy suben- 
docardial distribution to large transmural scars (49). These 
observations strongly support a role of repetitive ischemic 
injury and necrosis in the symptomatology and natural 
history of the disease. 
Mechanisms for ischemia. Several mechanisms are likely 
to be responsible for myocardial ischemia in hypertrophic 
cardiomyopathy. First, abnormal narrowing of the small 
intramural coronary arteries due to intimal and medial 
thickening in association with regions of myocardial fibrosis 
occurs in the majority of patients studied at autopsy (54). 
The role of this form of small vessel disease as a cause of 
ischemia is not yet clear. In addition, patients with hyper- 
trophic cardiomyopathy may have impairment of coronary 
vascular reserve and susceptibility to develop subendocar- 
dial ischemia that is characteristic of advanced secondary 
hypertrophy and related to a reduced capillary density (55). 
Third, the exacerbation of impaired relaxation and further 
elevation of left ventricular diastolic pressure during tachy- 
cardia or exercise in patients with hypertrophic cardiomy- 
opathy and secondary hypertrophy may itself further limit 
coronary perfusion, particularly in the subendocardium. 
This hypothesis is supported by the observation of Cannon 
et al. (51) that coronary blood flow actually decreases during 
pacing-induced angina in some of these patients. Fourth, 
there is experimental evidence (56) in models of pressure 
overload hypertrophy that myocardial hypoxia is accompa- 
nied by an impaired capacity to recruit anaerobic glycolysis. 
Preliminary studies (57) in patients with hypertrophic car- 
diomyopathy using positron emission tomography are con- 
sistent with a mismatch between impaired myocardial per- 
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fusion and utilization of glucose substrate, but further 
studies are needed to address this issue. 
Signijicancr of the Systolic Pressure Gradient 
The concept of outflow tract obstruction. The concept of 
left ventricular outflow obstruction has been criticized by 
investigators (58.59) who have argued that intraventricular 
gradients are related to gradients between rapidly and slowly 
emptying regions in association with cavity obliteration. 
Murgo et al. (60) also have challenged this notion on the 
basis of studies of aortic flow velocity, which suggested that 
patterns of flow were similar in patients with and without an 
outflow gradient and that both groups manifested the very 
rapid ejection of most of the left ventricular stroke volume 
very early in systole. However, multiple recent studies using 
cineangiographic, echocardiographic and Doppler flow 
methods lend support to the concept of “obstruction,” 
defined as ventricular emptying that occurs in the presence 
of a pressure gradient across the outflow tract. As recently 
summarized by Wigle (61) and Maron and Epstein (62). 
multiple studies indicate that the onset of septal-mitral leaflet 
contact correlates with both the development of the systolic 
gradient and the abrupt deceleration of aortic flow, whereas 
the time of onset and duration of contact predict the magni- 
tude of the gradient, the proportion of ventricular emptying 
that occurs in the presence of the gradient, and the prolon- 
gation of left ventricular ejection time. Furthermore. there 
are substantial data to support the hypothesis that septal- 
mitral leaflet contact occurs because of a Venturi effect of 
very rapid velocity of flow across the narrowed outflow tract 
in early systole (61). However, we support the concerns of 
many investigators in the field that the amount of energy that 
has been expended in the controversy of “proving” or 
“disproving” that obstruction exists has not yielded propor- 
tionate insight into our understanding of the ways in which 
the systolic gradient may contribute to symptoms or the 
natural history of the disease. 
Hypothesis of repetitive cycles of increased wall stress and 
oxygen demand leading to ischemia, necrosis and fibrosis. A 
different viewpoint is that the repetitive development of 
large systolic pressure gradients may be deleterious as a 
mechanical stimulus for further hypertrophy and because it 
is energy-costly in a hypertrophied ventricle with impaired 
coronary vascular reserve. This concept is supported by the 
observation that patients with left ventricular outflow ob- 
struction exhibit higher levels of myocardial oxygen con- 
sumption at rest and during pacing tachycardia in compari- 
son with patients without outflow obstruction (63). From this 
perspective, it is possible to have a unifying hypothesis that 
addresses the fact that symptoms of angina and exertional 
dyspnea and the development of myocardial fibrosis can 
occur in patients with classic asymmetric septal hypertrophy 
and outflow gradients, midventricular obstruction and dif- 
fuse hypertrophy with cavity obliteration. In each of these 
settings, the repetitive development of high levels of left 
ventricular systolic pressure may trigger a dangerous cycle 
of increased regional or global systolic wall stress and 
myocardial oxygen demand that provokes the development 
of ischemic injury, necrosis and fibrosis. 
This hypothesis is consistent with the well established 
observation that many patients with a large rest outflow 
gradient improve symptomatically after myotomy-myec- 
tomy. This improvement may be related to the ablation of 
regional myocardium involved in a vicious cycle of high wall 
stress and ischemia as opposed to the relief of “obstructed” 
blood flow. The advent of new technologies that will permit 
the assessment of global and regional changes in both 
myocardial perfusion and metabolism provide an exciting 
opportunity to address this hypothesis. 
Diastolic Function 
Abnormalities of left ventricular relaxation. The last 2 
decades have seen an explosion of international interest in 
diastolic function in hypertrophic cardiomyopathy and in 
secondary pressure overload hypertrophy. In both forms of 
hypertrophy. clinical congestive heart failure is a major 
cause of disability despite the preservation of left ventricular 
systolic function. In both forms of hypertrophy. left ventric- 
ular diastolic pressure is usually elevated relative to a normal 
or diminutive diastolic volume consistent with decreased 
diastolic distensibility of the left ventricular chamber. Simi- 
lar to secondary pressure overload hypertrophy (64). these 
findings are due in part to altered passive diastolic properties 
of the left ventricle related to both the extent of hypertrophy 
and changes in composition of the ventricle, including pos- 
sible alterations in the collagen matrix and deposition of 
fibrous scars (65). In addition, the elevation of left ventric- 
ular filling pressure is in part related to changes in the rate 
and extent of left ventricular pressure decay, that is, left 
ventricular relaxation (66). In some patients, left ventricular 
relaxation is so aberrant that left ventricular pressure con- 
tinues to decline sluggishly throughout diastole, instead of 
showing the usual pattern of decreasing rapidly to its nadir in 
early diastole at mitral valve opening (67). 
i%e responsible mechanisms for impuired left ventricular 
dirrstolic ,function are 0s yt incompletely understood and 
include a slowing of force inactivation at the level of the 
myofibril related to abnormal calcium handling, abnormal 
patterns of electromechanical activation, regional dyssyn- 
chrony of the time course of contraction and relaxation and 
impaired relaxation due to ischemia. Many but not all 
patients also show a slowed rate of left atria1 emptying and 
early left ventricular diastolic filling with an enhanced de- 
pendence on left atria1 contraction (66-69). These patients 
usually have an elevated left atria1 pressure, and thus the 
presence of impaired diastolic filling is striking because 
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elevation of left atria1 pressure and the driving force across 
the mitral valve would otherwise tend to accelerate left 
ventricular filling. 
Diastolic inflow obstruction of the left ventricle. The con- 
sistent finding of abnormal diastolic function in patients with 
the obstructive and nonobstructive forms of the disease has 
led to the hypothesis proposed by Goodwin (48) and others 
(66-69) that a major defect is diastolic “inflow obstruction” 
of the left ventricle. The elevation of diastolic pressure and 
the increased resistance to diastolic filling, which is espe- 
cially important when the diastolic filling period is shortened 
by tachycardia, contribute to symptoms of pulmonary ve- 
nous congestion and to easy fatigue and near syncope during 
exertion related to inadequate diastolic filling. Because of 
these abnormalities of diastolic function, the development of 
atria1 fibrillation is a “double whammy” that results in both 
abbreviation of the time available for diastolic filling and the 
loss of atria1 transport. 
Implications for Therapy 
Beta-blockers. For this reason, drugs such as beta- 
adrenergic blocking agents, which exert a primary myocar- 
dial effect of slowing relaxation and do not improve diastolic 
filling rates, may indirectly decrease dyspnea and increase 
exercise reserve through improved “diastolic function” by 
slowing the heart rate, lengthening the diastolic filling period 
and facilitating a greater extent of diastolic filling. 
Calcium channel blockers. The calcium channel blocking 
agents, such as verapamil, nifedipine and diltiazem, have 
been studied extensively and have been reported to improve 
left ventricular relaxation and the rate and extent of left 
ventricular filling in patients with both the obstructive and 
nonobstructive forms of the disease (67,69,70). Despite 
intense clinical study, the mechanisms of action are contro- 
versial and may include alteration of loading, induction of 
increased sympathetic tone, reduction of regional asyn- 
chrony and relief of subendocardial ischemia (71,72). A 
controversial issue that has not yet been answered is 
whether these agents exert a direct myocardial effect on 
cytosolic calcium handling in patients with hypertrophic 
cardiomyopathy. The benefit tends to be greatest in patients 
with severe elevation of left ventricular end-diastolic pres- 
sure and impairment of relaxation and filling, but the effects 
of these agents on diastolic function are not uniform and 
precipitation of pulmonary edema can occur. Although im- 
provement in diastolic function has also been observed with 
short-term administration of amiodarone, similar to that seen 
with calcium blockers, long-term therapy has been associ- 
ated with the elevation of left heart filling pressures and no 
improvement in diastolic relaxation (73). 
Side effects. Although calcium channel blockers have 
been an important addition to treatment options, these 
agents must be used with great caution because of their 
chronotropic side effects (bradycardia and isorhythmic dis- 
sociation with loss of atria1 contraction with verapamil and 
reflex tachycardia with nifedipine) and the risk of excessive 
vasodilation and hypotension with both agents (74,75). Thus, 
the quest for the ideal lusitropic agent to reliably enhance left 
ventricular relaxation has not been fulfilled with available 
agents and merits further investigation by both academic 
research centers and the pharmaceutical industry. 
The Dilemma of Sudden Death 
Predictors of sudden death. Since the initial case reports, 
sudden cardiac death has been an ominous feature of hyper- 
trophic cardiomyopathy distinct from its hemodynamic ab- 
normalities. Similar to dilated cardiomyopathy, major unan- 
swered problems are the ability to identify individual 
patients at high risk of sudden death and to define treatment 
strategies that reduce this risk. Although the overall annual 
mortality rate for patients studied at referral centers is 
estimated to be 2 to 3%, the risk of premature death is 
skewed by a high incidence of sudden cardiac death in 
children and young adults (39,49,76). In about 50% of 
patients, death occurs suddenly, is unexpected and can be 
the index presentation of hypertrophic cardiomyopathy. 
Ominous prognostic features for an increased risk of sudden 
death include young age (first 3 decades of life), documented 
syncope and a family history of sudden death (39). It is still 
controversial whether the extent of hypertrophy is an inde- 
pendent predictor of sudden death. Otherwise, it is not 
predicted by symptoms, functional limitation, hemodynamic 
abnormalities including the presence or absence of left 
ventricular outflow obstruction or rest ECG abnormalities 
(40,49). 
Mechanisms. In this disorder, sudden cardiac death can 
probably occur from multiple mechanisms including hemo- 
dynamic deterioration, complete heart block, bradyarrhyth- 
mias and atria1 tachycardia with concealed atrioventricular 
(AV) conduction. However, the predominant mechanism is 
probably the development of a sustained ventricular tach- 
yarrhythmia. Although this condition has been documented 
only rarely as a cause of witnessed sudden death (77), 
several centers (78,79) have reported that asymptomatic 
episodes of ventricular tachycardia detected by ambulatory 
Holter ECG monitoring are predictive of an increased risk of 
sudden death in adults. In patients referred to the National 
Institutes of Health, a single episode of ventricular tachy- 
cardia during ambulatory monitoring was associated with an 
8% risk of sudden death per year, compared with a 1% risk 
in patients without ventricular tachycardia (79). The mech- 
anisms responsible for the initiation of ventricular tachycar- 
dia in these patients including the potential contribution of 
ischemia, are not known. 
Prevention: role of beta-adrenergic blockers. Beta- 
adrenergic blocking agents have been used widely as an 
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antidote to reduce the risk of sudden death in both sympto- 
matic adults and asymptomatic children and young adults in 
whom hypertrophic cardiomyopathy is detected incidentally 
by routine physical examination or screening echncardiog- 
raphy. The rationale for use of these drugs is bolstered by 
awareness of the potential role of ischemia in this disorder 
and the striking protective effect of beta-adrenergic blockers 
in reducing mortality in patients after myocardial infarction 
and possibly in patients with dilated cardiomyopathy. How- 
ever, the effect of beta-blockers on the risk of sudden death 
in hypertrophic cardiomyopathy is not established. Propran- 
0101 administration does not appear to reduce the frequency 
of asymptomatic ventricular arrhythmias detected by Holter 
monitoring, and studies by McKenna et al. (80) in the United 
Kingdom have failed to demonstrate a protective effect of 
propranolol against sudden death. However, prospective, 
controlled, randomized trials have not been done to deter- 
mine whether administration of beta-adrenergic blockers 
modifies the risk of sudden death in high risk young adults. 
Other antiarrhythmic agents. There are also considerable 
controversy and few hard data regarding the efficacy of 
classic type 1 agents (quinidine, procainamide) in suppress- 
ing ventricular arrhythmias and preventing sudden death. 
Preliminary studies using amiodarone are promising. Avail- 
able clinical trials that did not incorporate randomized 
controls suggest that amiodarone reduces the frequency of 
episodes of ventricular tachycardia detected by ambulatory 
monitoring and may be more effective than conventional 
agents including calcium channel blockers (81,82). However. 
there is a great concern about the long-term use of this agent 
in children and young adults because of the difficulty of 
evaluating efficacy, its proarrhythmic effects. its deleterious 
effects on left heart filling pressure and its uncommon but 
major side effects including pulmonary fibrosis. The poten- 
tial role of invasive electrophysiologic testing to identify high 
risk patients and monitor efficacy of therapy and the use of 
implantable defibrillators in preventing sudden death also 
needs further study. 
Unresolved: The Causes of 
Hypertrophic Cardiomyopathy 
Familial transmission. There is some uncertainty regard- 
ing the true prevalence of familial versus sporadic forms of 
hypertrophic cardiomyopathy, which is influenced in part by 
the techniques used to detect occult disease (echocardio- 
graphic criteria for example) and the fact that morphologic 
expression of the disease may not be apparent until young 
adulthood. With these caveats, hypertrophic cardiomyopa- 
thy appears to be familial in nearly 60% of cases and 
sporadic in the remainder (83,84). A single pattern of inher- 
itance is not characteristic, an observation that suggests that 
several genetic defects may contribute to the pool of patients 
now diagnosed as having hypertrophic cardiomyopathy. 
However. in about 75% of pedigrees with familial transmis- 
sion, the pattern of inheritance is consistent with a single or 
linked gene defect of autosomal dominant transmission with 
variable penetrance and expression. Within pedigrees with 
familial transmission, there is marked variability of cardiac 
morphology, including the site of hypertrophy and functional 
limitation. 
Neurohormonal factors and hypertension. The fact that 
morphologic evidence of hypertrophy may not be evident 
until after the pubertal growth spurt suggests that neurohor- 
monal factors, including reproductive hormones, play a 
poorly understood role in modulating the expression of 
hypertrophy. The variability of expression also suggests 
that. in genetically susceptible patients, the development of 
hypertrophy may be modulated by exposure to other 
stresses, such as mechanical stress imposed by athletic 
activity or even mild hypertension. The role of pressure 
overload as a possible stimulus for the development of 
severe hypertrophy in genetically susceptible individuals has 
been neglected, in part because of the focus on the “pure” 
forms of unexplained hypertrophy without contamination by 
factors such as hypertension. It is noteworthy that hyper- 
tension was present in the early case report by Brock (29). In 
this regard, there is new recognition of the syndrome of 
hypertensive hypertrophic myopathy, which is defined as 
the presence of severe left ventricular hypertrophy in older 
patients with a variable history of hypertension in which 
symptoms, cardiac geometry, presence of mitral annular 
calcification and systolic and diastolic function simulate 
hypertrophic cardiomyopathy in the elderly (8.5). Careful 
pedigree analysis, histologic studies and ultimately advances 
in molecular biology are needed to clarify whether this 
syndrome is completely distinct from hypertrophic cardio- 
myopathy in the elderly (86) or is possibly a phenotypic 
expression of hypertrophic cardiomyopathy that is triggered 
by the appearance of systolic hypertension during aging (87). 
Genetic defects. An important future direction in hyper- 
trophic cardiomyopathy will be the confirmation or refuting 
of the hypotheses that the familial form is a single gene 
defect with protean manifestations or a combination of 
several separate genetic defects. Available pooled data sug- 
gest an increased frequency of HLA DR4, A9, BS and B40 
antigens in populations of patients with hypertrophic cardio- 
myopathy, which lends support to a genetic component; 
however. as yet there has been a failure to demonstrate HLA 
antigen or other gene product linkage within families to 
support the concept that hypertrophic cardiomyopathy has a 
single or closely linked gene loci that determine disease 
susceptibility (88,89). Attempts are ongoing to use contem- 
porary molecular genetic techniques to identify a linkage 
between specific gene products and the expression of the 
disease to ultimately identify and characterize specific de- 
ranged deoxyribonucleic acid (DNA) segments and their 
chromosomal location. Advances in this direction will be 
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important not only in developing highly accurate and sensitive in these patients. These observations do not exclude the 
markers of this uncommon disease, but also in attempting to hypothesis that defective interplay between the cardiac cell 
understand the genetic loci that are critical in the regulation of and catecholamines may occur in utero and may not be 
cardiac hyperplasia and hypertrophy in general. detectable during later development. 
Biologic defects. Just as the critical gene loci are not 
known, the biologic defects responsible for the expression of 
hypertrophic cardiomyopathy are not known. It is intriguing 
that there are case reports of the development of cardiac 
malformations that mimic hypertrophic cardiomyopathy 
morphology and function in patients with hereditary subcel- 
lular defects of skeletal and cardiac muscle, such as hered- 
itary mitochondrial myopathy (90) and myotonic muscular 
dystrophy (91), and in patients with hereditary storage 
disorders such as Fabry’s disease (92). These rare experi- 
ments of nature suggest that the phenotypic expression of 
hypertrophy seen in hypertrophic cardiomyopathy can occur 
as a response to diverse developmental defects in which 
a common defect is a paucity of normal stress-bearing 
myocytes. 
Defective response of developing cardiac cells to sympa- 
thetic stimulation. Two hypotheses to explain the develop- 
ment of hypertrophic cardiomyopathy are currently under 
scrutiny. Goodwin (2), Perloff (93) and Ferrans and Rodri- 
guez (94) have developed the hypothesis that familial hyper- 
trophic cardiomyopathy is caused by a defective response of 
developing cardiac cells to sympathetic stimulation. This 
causes a failure of regression of the fetal pattern of dispro- 
portionate septal thickening and myofiber disarray that re- 
sults in the fetal “programming” of permanently disturbed 
numbers and regional distribution of myocytes available to 
hypertrophy in response to later developmental stimuli. 
Support for the hypothesis comes from the association of 
hypertrophy with other congenital disorders of neural crest 
origin, such as neurofibromatosis, lentiginosis and pheochro- 
mocytoma, and from experimental studies in animals and 
myocyte culture that have shown that administration of 
nerve growth factor, a glycoprotein that enhances sympa- 
thetic nerve growth, and norepinephrine can stimulate the 
development of hypertrophy. Support is also drawn from the 
apparent hyperdynamic contractile state in hypertrophic 
cardiomyopathy and from the clinical improvement seen 
with beta-adrenergic blockers. The perception that the hy- 
pertrophied myocyte is a hyperdynamic “superman” that 
can be tamed by negative inotropic agents has been seriously 
challenged by recent studies (95,96) of stress-shortening and 
end-systolic pressure-volume relations in patients with hy- 
pertrophic cardiomyopathy, which indicate that myocardial 
contractility is normal or depressed and not hyperdynamic. 
Kawai et al. (97) reported the presence of normal plasma and 
elevated myocardial catecholamine content in patients with 
hypertrophic cardiomyopathy, but others (98,99) have failed 
to substantiate altered levels of myocardial cyclic adenosine 
monophosphate (AMP), beta-adrenergic receptor density or 
adenylate cyclase activity in response to adrenergic agonists 
Defective regulation of cytosolic calcium: atinormal calcium 
regulation. A second hypothesis is that the unique biologic 
defect in hypertrophic cardiomyopathy is the defective reg- 
ulation of cytosolic calcium. This hypothesis is supported by 
the clinical association of hypercalcemia and hypertrophic 
cardiomyopathy (loo), the apparent hyperdynamic contrac- 
tile state and the impairment of diastolic relaxation that can 
be induced by experimental calcium overload (101). The 
concept of abnormal calcium regulation has provided an 
attractive rationale for the use of calcium channel blockers in 
hypertrophic cardiomyopathy. Recently, Morgan and Mor- 
gan (102) studied myocardial tissue obtained at surgery from 
patients with hypertrophic cardiomyopathy and reported 
that this cardiac muscle showed a marked prolongation of 
the cytosolic calcium transient in association with a prolon- 
gation of the time course of tension decay. However, sub- 
sequent studies from this laboratory (103) have shown sim- 
ilar changes in the intracellular calcium transient in 
association with secondary pressure overload hypertrophy. 
As recently reviewed elsewhere (64), current data strongly 
suggest that changes in the regulation of calcium by the 
sarcoplasmic reticulum and the sarcolemma are not unique 
to hypertrophic cardiomyopathy but instead are a character- 
istic adaptation of advanced pressure overload hypertrophy. 
Thus, impaired regulation of cytosolic calcium is a likely 
candidate as an important pathogenic mechanism in hyper- 
trophic cardiomyopathy, particularly when the stress of 
ischemia, which further impairs calcium handling, is super- 
imposed. However, available evidence does not yet support 
the hypothesis that calcium overload is the primary geneti- 
cally determined defect in hypertrophic cardiomyopathy. 
Restrictive Cardiomyopathy 
Definition and etiology. Of all the forms of cardiomyopa- 
thy, this type is the one encountered least frequently. In its 
classic form, restrictive cardiomyopathy manifests as con- 
gestive heart failure with a small or only mildly enlarged 
heart, mimicking constrictive pericarditis. The pathophysiol- 
ogy is that of impaired diastolic function, attributable to 
decreased ventricular distensibility and impairing diastolic 
filling secondary to morphologic changes in the endocardium 
or myocardium or both. In the tropics, the most prevalent 
form of restrictive cardiomyopathy is endomyocardial fi- 
brosis, which is not really a disease of heart muscle, but 
primarily a disease of the endocardium, which becomes 
scarred and thickened, leading to restriction of ventricular 
filling and diastolic dysfunction (26). However, the suben- 
docardial myocardium is often involved, as are the AV 
valves, which become insufficient. Characteristically, the 
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outflow tract is spared. In the Ivory Coast, 20% of deaths 
due to heart failure before age of 40 are attributed to this 
disease (26). 
Tropical endomyocardial fibrosis was first reported in 
1946 by Bedford and Konstam (104). Ten years earlier. 
Loffler (105) in Switzerland had described a similar disease 
in the West, associated with eosinophilia, which he named 
endocarditis parietalis fibroplastica and that has since be- 
come known as Loffler’s endocardial fibrosis and has been 
reported from several developed countries. More recently, it 
has been proposed that these are related or identical dis- 
eases, the eosinophilia having preceded the clinical manifes- 
tations and being observed only rarely in the tropics (106). 
The cardiac manifestations have been reported to be asso- 
ciated with degranulation of eosinophils and their severity to 
be a function of the severity and duration of eosinophilia. 
Thus, a pathogenetic role has been attributed to degranula- 
ted eosinophils, which have been found to bind immuno- 
gammaglobulin IgG and have an increased peroxidase, 
which in turn was demonstrated to have direct toxic effects 
on rat myocytes (107). 
In the West, myocardial restriction is more common than 
endocardial restriction. The most frequent forms are idio- 
pathic myocardial fibrosis and amyloid heart disease, the 
latter by definition really failing into the category of “specific 
heart muscle disease.” Other specific heart muscle diseases, 
such as hemochromatosis, sarcoid heart disease, myocardial 
infiltration by tumor. Fabry’s disease and radiation fibrosis 
may also present as restrictive cardiomyopathy (108). In these 
instances, the constitutive properties of the ventricular wall 
are altered: the diffuse increase in fibrous tissue, infiltration 
by tumor or deposits of foreign substances, for example 
amyloid, stiffen ventricular walls and thus prevent normal 
dilation of ventricular chambers during diastole, eventually 
reducing stroke volume and cardiac output. However, the 
syndrome of restrictive cardiomyopathy has also been ob- 
served in the absence of histopathologic abnormalities of the 
endocardium or myocardium (109). Some of these cases are 
attributable to concentric hypertrophy (110). A neglected 
potential mechanism has been alteration of collagen and the 
cytoskeleton, such as described by Caulfield (11 I). 
Diagnosis. The diagnosis of restrictive cardiomyopathy, 
the rarest form of cardiomyopathy, should be entertained in 
patients who present with congestive heart failure in the 
presence of slight or no cardiomegaly, and the principal 
differential diagnosis is constrictive pericarditis. Chest pain 
is not unusual. Elevation of jugular venous pressure is 
usually quite prominent. Murmurs of mitral or tricuspid 
regurgitation, or both, may be heard. Atrial arrhythmias, the 
brady-tachycardia syndrome, or complete heart block may 
be present (112,113). In late cases, the ECG may show low 
voltage. Noninvasive evaluation and hemodynamic study 
tend to confirm preservation of normal or near normal 
systolic function in the presence of elevated but not equal 
left and right ventricular filling pressures. The square root 
sign (diastolic dip and end-diastolic plateau) is often present. 
All patients with restrictive pathophysiology should un- 
dergo endomyocardial biopsy (114) to rule out specific heart 
muscle disease such as amyloidosis. If the histologic features 
are normal or near normal, constrictive pericarditis should 
be reconsidered even if echocardiography did not suggest 
this possibility. Computed tomographic scanning has also 
been found of value in the differential diagnosis (115). 
Treatment. When one sees the extreme interstitial fi- 
brosis or deposition of amyloid surrounding cardiac 
myocytes. individually or in clusters, it is difficult to think of 
therapeutic interventions other than nonspecific supportive 
measures, such as diuretics and vasodilators in cases of 
congestive heart failure. Even here, caution must be exer- 
cised because elevated ventricular filling pressures may be 
needed for adequate stroke volume and cardiac output. On 
the other hand, as long as idiopathic cases exist without such 
morphologically evident “restriction,” the search must con- 
tinue for other mechanisms that might lead to specific ther- 
apy. For example, vascular lesions and spasm resulting in 
&hernia have been incriminated in the myocardial fibrosis 
encountered in scleroderma (116). Contraction band necrosis 
of myofibers (117) and abnormal thallium scans in the pres- 
ence of normal coronary angiograms (I 18) point in this 
direction. Radiation-induced myocardial fibrosis also appears 
to involve damage to the myocardial microvasculature. 
Endocardial$broelastosis, usually of unknown etiology, 
has been reported in association with carnitine deficiency 
(I 19). Clinically, the detection of low serum carnitine levels, 
especially in cases of familial cardiomyopathy or endocardial 
thickening demonstrated by biopsy. may lead to specific 
therapy with L-carnitine. Another specific heart muscle 
disease. which may present as specific restrictive cardiomy- 
opathy and be amenable to specific therapy, is hemochro- 
matosis (120); myocardial deposits of iron can be reduced by 
means of phlebotomies (121) or by chelation (122), resulting 
in functional improvement. Endomyocardial fibrosis may be 
treated surgically by endocardiectomy and repair or replace- 
ment of affected AV valves (123). Antihypereosinophilic 
therapy for the hypereosinophilic syndrome with prednisone 
or hydroxyurea, or both, has been recommended (124). 
Surprisingly, calcium channel blockers, which are known to 
improve ventricular diastolic function in hypertrophic car- 




As indicated before, clinical and pathophysiologic mani- 
festations of dilated cardiomyopathy have been well charac- 
terized and are widely known. The characteristic features 
are impaired systolic function of both ventricles, although 
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dysfunction of one ventricle may dominate, leading to man- 
ifestations of congestive heart failure. In individuals who 
have a sedentary lifestyle and low sodium intake, or who are 
receiving diuretic therapy, even severe systolic dysfunction 
may not be accompanied by pulmonary or systemic conges- 
tion, but rather manifest as easy fatigue and decreased 
exercise tolerance. Although most clinical cases are recog- 
nized when manifestations of heart failure appear, initial 
presentations as cardiac arrhythmia, conduction distur- 
bance, thromboembolic complication or even sudden death 
are not uncommon. Such manifestations may even occur 
before significant ventricular dilation or hemodynamic im- 
pairment of myocardial function can be demonstrated. 
Although biventricular global hypokinesia, in the absence 
of risk factors and symptoms of coronary artery disease, 
would generally permit a clinical diagnosis of dilated cardio- 
myopathy, especially in young patients, coronary disease 
may present in just this manner, and dominance of right or 
left ventricular dysfunction, regional hypokinesia, as well as 
chest pain may all occur in dilated cardiomyopathy. 
Arrhythmogenic right ventricular dysplasia. A cardiomy- 
opathy limited to the right ventricle, associated with arrhyth- 
mias and sudden death, especially in young people, has 
drawn increasing attention (125-127). This rare form of 
cardiomyopathy is also known as arrhythmogenic right 
ventricular dysplasia, Uhl’s anomaly or parchment heart. 
Right ventricular myocardium is thinned, partly to com- 
pletely replaced by fibrous or adipose tissue, and the right 
ventricle is dilated and hypokinetic. Supraventricular and 
especially ventricular arrhythmias are characteristically 
present. Premature death results from early congestive heart 
failure or sudden, presumably arrhythmic death, which may 
be the first known manifestation of the disease and not 
infrequently is associated with physical exertion. Evidence 
for familial occurrence of this condition has been reported 
from Italy (128). 
Natural course and prognosis. The natural course and 
prognosis of dilated cardiomyopathy are a function of how 
early the diagnosis is made. Whereas the annual mortality 
rate, beginning with the onset of illness, was as low as 5.7% 
in a series of 258 patients reported on by Kuhn et al. (129), 
a 1 year mortality rate of 23% and a 2 year mortality rate of 
48% have been reported in 87 patients with severe conges- 
tive heart failure (130). There is general agreement that 
significant cardiomegaly, low cardiac output and frank con- 
gestive heart failure are associated with a poor prognosis 
(5,131). In some series, the severity of histopathologic 
abnormalities on myocardial biopsy correlated inversely 
with life expectancy (129). Cardiac hypertrophy has a favor- 
able effect on prognosis (132) presumably by limiting sys- 
tolic wall stress. The presence of etiologic or contributory 
factors that can be eliminated, for example ethanol, thiamine 
deficiency, hypertension, anemia and thyrotoxicosis, also 
may affect the prognosis favorably. 
Pathogenesis 
Tabulations of “causes” of dilated cardiomyopathy, 
namely specific agents, diseases and associated syndromes, 
have been published repeatedly (l-6,8-12). These include, of 
course, specific heart muscle diseases. Here, we shall focus 
on proved and postulated pathogenetic mechanisms that 
may play a role in dilated cardiomyopathy. 
Heredity. The familial occurrence of dilated cardiomyop- 
athy is best known in the specific heart muscle diseases 
associated with hereditary disorders such as glycogen stor- 
age diseases, Fabry’s disease, mucopolysaccharidosis, the 
muscular dystrophies and Friedreich’s ataxia. Specific bio- 
chemical and metabolic abnormalities have been identified in 
many of these disorders, although cardiac tissue itself has 
only rarely been studied. 
The familial incidence of dilated cardiomyopathy has 
been given less attention. In a retrospective analysis (133) of 
169 patients, the family history was positive in 6.5% of 
cases. Recently, X-linked, autosomal dominant and auto- 
somal recessive inheritances of dilated cardiomyopathy have 
been reported (134-136). The use of echocardiography in 
systematic surveys of relatives of patients with dilated 
cardiomyopathy promises to reveal a familial prevalence 
much more frequently than heretofore suspected (137). 
A fatal dilated cardiomyopathy in newborn calves has 
been attributed to a genetic defect (138). The hereditary 
cardiomyopathy of the Syrian hamster, transmitted by an 
autosomal recessive gene, has long been a favorite experi- 
mental model of dilated cardiomyopathy (139). Major histo- 
compatibility genes have been shown to play a role in the 
determination of myocardial damage and the immunologic 
mechanisms involved in infection with cardiotropic viruses 
(140-142). 
It is not unreasonable to expect that within a few years it 
may become possible to identify individuals genetically 
predisposed to myocardial disease and to reduce that risk by 
control of other risk factors, such as ethanol and viral 
infections. 
Nutritional deficiencies. Thiamine deficiency. One of the 
very few curable, as well as preventable, dilated cardiomy- 
opathies is wet beriberi, which is due to deficiency of 
thiamine or vitamin B,, a coenzyme essential to the decar- 
boxylation of alpha-keto-acids and in the utilization of pen- 
tose in the hexose monophosphate shunt. In the absence of 
thiamine, oxidative phosphorylation and hence myocardial 
energy production are impaired. Clinically, thiamine defi- 
ciency first manifests as a high output state, secondary to 
peripheral vasodilation, at least in part attributable to the 
accumulation of intermediate carbohydrate metabolites. 
Eventually, the depressed myocardial function in the face of 
increased preload and wall stress leads to congestive heart 
failure, first in the presence of normal to high cardiac output, 
later in association with a low output state. This sequence is 
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of great interest inasmuch as the peripheral vasodilation 
undoubtedly acts to delay the onset of left ventricular 
failure. Indeed, administration of thiamine, resulting in re- 
versal of the peripheral vasodilation, has been reported to 
precipitate left ventricular failure (143). A similar protective 
role of naturally occurring left ventricular unloading by 
peripheral vasodilation is seen in hyperthyroidism and in 
cirrhosis of the liver. 
Selenium deficiency. Another treatable as well as pre- 
ventable form of dilated cardiomyopathy is that due to 
selenium deficiency, reported primarily in northeast China, 
where it is known as Keshan disease (144). The absence of 
selenium results in decreased activity of glutathione perox- 
ide, an enzyme dependent on selenium. as well as an 
increase in free radicals that may be toxic to cardiac 
myocytes. Clinical cardiomyopathy due to a deficiency in 
selenium has also been reported from the West (145). 
Carnitine dejciency. Deficiency of carnitine may present 
as dilated cardiomyopathy. In this condition, oxidation of 
fatty acids is impaired and lipids accumulate in the cyto- 
plasm. The deficiency may be familial, and the cardiac 
lesions are often associated with endocardial fibroelastosis. 
Oral therapy with L-carnitine is effective (119). Recent 
reports of therapeutic benefit of carnitine treatment in the 
cardiomyopathic hamster (146) and in experimental 
Adriamycin (doxorubicin hydrochloride) toxicity (147) raise 
the possibility that carnitine deficiency may be a contribu- 
tory factor in human cardiomyopathies as well. Indeed, 
Regitz et al. (148) reported reduced myocardial carnitine 
levels in 30 patients with end-stage heart failure secondary to 
cardiomyopathy, but also in 22 patients with heart failure 
secondary to coronary disease. 
Toxins and drugs. Ethanol. In many populations and 
series of patients with dilated cardiomyopathy, a history of 
chronic alcoholism is so prominent that some consider 
ethanol the major cause of dilated cardiomyopathy (149). 
Although Mackenzie (150) introduced the term “alcoholic 
heart disease” in 1902, in the first half of this century 
congestive heart failure in patients with chronic alcoholism 
was generally attributed to nutritional deficiencies. In 1957, 
however, Brigden and Robinson (15 1) reintroduced “alco- 
holic heart disease.” Indeed, depression of myocardial func- 
tion by chronic intake of ethanol has been well demonstrated 
in humans as well as in experimental animals (152-155). 
However. many efforts to produce chronic congestive heart 
failure by administration of ethanol alone in animal models 
have failed. Most recently, however, Edes et al. (156) 
succeeded in producing dilated cardiomyopathy in young 
turkeys fed ethanol. accounting for 35% of caloric intake, for 
16 weeks. Considerable evidence favors the view that other 
factors may be needed for full expression of the clinical 
syndrome of dilated cardiomyopathy, including genetic pre- 
disposition, malnutrition, infection and other toxins (23.157). 
There is increasing evidence for a role of altered handling of 
calcium, the effects of which may be prevented by verapamil 
(158). Clinically, the identification of a history of alcoholism 
in a patient with dilated cardiomyopathy is important inas- 
much as the prognosis may be improved by abstention. 
Anthrtrcyclines. Doxorubicin (Adriamycin) and daunoru- 
bicin, among the most effective agents in the chemotherapy 
of malignant neoplasms, are highly cardiotoxic. The chronic 
effects, which include dilated cardiomyopathy, have been 
studied extensively in humans as well as experimental ani- 
mals. These studies lead to the conclusion that we may be 
dealing with a multifactorial pathogenesis. including altered 
nucleic acid synthesis (159). altered mitochondrial respira- 
tion ( 160). release of vasoactive substances ( 16 I), formation 
of free radicals (162) and calcium overload (163). 
Vasoactive agents and microvascular spasm. Studies of 
cardiac effects of catecholamines have dealt primarily with 
acute effects, including myocardial necrotic foci resembling 
ischemic lesions, that have been attributed to microvascular 
spasm and hypoxia, altered membrane permeability and 
calcium overload (164). Late effects of acute administration 
of isoproterenol to rats, however. include cardiomyopathy 
and congestive heart failure (165). Catecholamine-induced 
dilated cardiomyopathy in humans is seen most clearly in 
patients with pheochromocytoma. This form of cardiomyop- 
athy is reversible by removal of the tumor or by adrenergic 
blockade (166,167). 
Of wider interest is the evidence that catecholamines play 
a role in anthracycline cardiotoxicity (161) and diabetic 
cardiomyopathy (168). Catecholamines also enhance the 
severity of necrosis seen in the hereditary cardiomyopathy 
of the Syrian hamster (169). 
Recent studies of experimental models oj’ curdiomyopa- 
thy have revealed evidence of microvascular spasms in the 
cardiomyopathic hamster (170), the hypertensive-diabetic 
rat I 171) and the mouse infected with Trypanosoma cruzi 
(172). Furthermore, these lesions could be prevented by 
verapamil, suggesting that calcium overload plays a role in 
these experimental models, which closely resemble the 
human disease. 
Decreased coronary flow reserve. The frequent occur- 
rence of chest pain, often indistinguishable from angina 
pectoris. in patients with dilated cardiomyopathy has long 
puzzled clinicians and has led to the postulate of a decrease 
in maximal coronary blood flow (173). Cannon et al. (174) 
studied the responses of coronary blood flow in 26 patients 
with dilated cardiomyopathy and angiographically normal 
coronary arteries to ergonovine, dipyridamole and rapid 
atrial pacing. In the subset of patients with a history of 
angina pectoris, there was a greater response to ergonovine 
and a significantly decreased coronary flow reserve in re- 
sponse to either dipyridamole or pacing. Recently, DeMarco 
et al. (175) reported evidence that in patients with chronic 
heart failure due to either chronic coronary artery disease or 
dilated cardiomyopathy, both rest coronary blood flow and 
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myocardial oxygen consumption were increased and coro- 
nary sinus oxygen content was decreased. Although the 
mechanism of this decreased coronary flow reserve remains 
uncertain, myocardial hypoxia not only may explain the 
angina1 pain, but also may be implicated as a factor poten- 
tially contributing to ongoing myocyte necrosis, replacement 
fibrosis and deterioration of myocardial function. 
Tachyarrhythmia. Reversible heart failure associated 
with rapid supraventricular arrhythmias has been recognized 
in patients without evidence of heart disease for some time 
(176). In a recent report, Packer et al. (177) described eight 
subjects with uncontrolled tachycardia of long standing 
associated with depressed left ventricular function, which 
was at least partly reversed by control of the tachycardia. 
They thus coined the term “tachycardia-induced cardiomy- 
opathy.” It is, of course, possible that they were dealing 
with subclinical cardiomyopathy enhanced by tachycardia. 
On the other hand, heart failure has been induced by 
chronic, rapid cardiac pacing in healthy dogs, followed by 
persistence of abnormal cardiac function on return to sinus 
rhythm (178). Underlying mechanisms may include shorten- 
ing of diastole, depletion of high-energy substrate (179) and 
ischemia secondary to decreased coronary flow reserve (see 
earlier discussion). Evidence that supraventricular tachycar- 
dia depresses both systolic and diastolic myocardial reserve 
in patients with established dilated cardiomyopathy was 
recently reported by Feldman et al. (180), and studies (181) 
of isolated cardiac muscle from patients with end-stage heart 
failure yielded evidence for calcium overload and decreased 
concentrations of cyclic adenosine monophosphate at high 
frequencies of stimulation. 
Calcium overload. The important role of calcium in exci- 
tation/contraction coupling and, hence, in the pump function 
of the heart has long been recognized (182-184). Increasing 
evidence, derived from studies of both clinical and experi- 
mental cardiomyopathies, points toward abnormalities in the 
handling of calcium by heart muscle cells. Thus, there is 
evidence of impaired calcium regulation in several experi- 
mental models of cardiomyopathy. Myocardial calcium is 
increased in the cardiomyopathic hamster (185,186). Left 
ventricular function is improved by the calcium blocker 
verapamil (187). Calcium overload has also been demon- 
strated in experimental Adriamycin toxicity (163). In healthy 
Syrian hamsters fed ethanol until adenosine and high energy 
phosphates along with left ventricular function became de- 
pressed, administration of verapamil along with ethanol was 
shown to have a preventive effect (158). On the other hand, 
streptozotocin-induced diabetes in the rat was associated 
with depression of the calcium pump, reversible by insulin 
(188). Recent studies (189) of human heart muscle from 
patients with end-stage heart failure, including cases of 
dilated cardiomyopathy, also yielded evidence of abnormal 
intracellular calcium handling. 
Oxygen free radicals. Oxygen free radicals have been 
recognized as toxins that may play a role in several disease 
processes, of which ischemia/reperfusion injury has been 
given special attention (190,191). The formation of free 
radicals has been reported in the cardiomyopathy of the 
Syrian hamster (192), as well as in Adriamycin toxicity (162). 
In acute but not in chronic experimental Adriamycin cardio- 
myopathy, the free radical scavenger alpha-tocopherol (vi- 
tamin E) has been found to be of protective value (193). 
Infection. All infectious organisms that are capable of 
invading the blood stream may enter the myocardial capil- 
laries and reach the myocardium. Acute necrotic or inflam- 
matory lesions have been associated with many bacterial, 
spirochetal, rickettsial, viral, mycotic, protozal and helmin- 
thic infections (5,9). Some forms of acute myocarditis have 
long been recognized as precursors of chronic dilated car- 
diomyopathy. Thus, both clinical and experimental studies 
have established that the chronic dilated cardiomyopathy so 
prevalent in Central and South America and known as 
Chagas’ disease is a late sequel of acute myocarditis due to 
Trypanosoma cruzi (194-196). Dilated cardiomyopathy has 
also been recognized as a late sequel of African trypanoso- 
miasis (197) and of toxoplasmosis (198). 
Viral myocardiris. Increasing evidence also points to 
dilated cardiomyopathy as a late sequel to acute viral myo- 
carditis (199). This evidence includes clinical follow-up 
studies (200-206). Support of such a relation has also come 
from serologic surveys of patients with chronic dilated 
cardiomyopathy (207-209). 
Not all viruses, however, are myotropic and not all 
patients infected with myotropic viruses develop myocar- 
ditis or dilated cardiomyopathy, or both. This observation 
should not surprise, in view of the great differences in 
susceptibility to and expression of cardiac involvement by a 
given virus seen in different inbred strains of rodents 
(140,141). Although it has been postulated that the majority 
of cases of idiopathic dilated cardiomyopathy in countries in 
which Trypanosoma cruzi is not endemic may be of viral 
origin (48,210), the fraction of cases for which this holds true 
is unknown. 
HIV virus (AIDS). Acute as well as chronic dilated 
cardiomyopathy is encountered with increasing frequency in 
patients with acquired immunodeficiency syndrome (AIDS) 
(211), often associated with evidence of myocarditis (212). 
The majority of cases remained unrecognized before post- 
mortem examination and may have been associated with 
opportunistic infections. However, HIV virus has been 
cultured for myocardial tissue at least once (213), although it 
may have originated from perfusing blood. As yet, cardiac 
involvement has not been reported to occur in experimental 
models of infection with this or related viruses. Therefore, it 
remains an open question whether the HIV virus itself is 
responsible for cardiomyopathy. 
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Experimental myocarditis. Strong support for dilated 
cardiomyopathy as a sequel to acute myocarditis also is 
provided by extensive studies of experimental models of 
myocarditis. Thus, the chronic form of Chagas’ disease has 
been reproduced in mice (196), and chronic cardiomyopathy 
has been demonstrated to develop in mice infected with 
encephalomyocarditis virus (214,215), herpes simplex virus 
(216) and especially with coxsackievirus B3 (217) and B4 
(218). 
Subacute and c,hronic myocarditis. Myocarditis may also 
be subacute and even chronic. In humans, this condition was 
first described in 1931 by Boikan (219), who coined the label 
“myocarditis perniciosa.” Additional cases were reported 
by Kline and Saphir (220). With increasing use of endomyo- 
cardial biopsy (221) in patients with chronic dilated cardio- 
myopathy, the persistence of active inflammation and necro- 
sis has been reported in 3% to 63% of such cases, especially 
if heart failure was <I year’s duration (222-226). This 
variability may, in part, be attributed to variable criteria for 
the histopathologic diagnosis of myocarditis (227). However, 
since the establishment of strict criteria for the histopatho- 
logic diagnosis of active myocarditis (228). the prevalence of 
active myocarditis among patients with dilated cardiomyop- 
athy has been reported to be closer to 10% (229). Chronic 
myocarditis associated with demonstrably persistent Trypa- 
nosoma cruzi infection has also been described (230). 
Recent application oj’in situ hybridization techniques to 
the study qf’ the pathogenesis of ongoing mgocarditis re- 
vealed that encephalomyocarditis viral nucleic acid in car- 
diac myocytes was no longer present 2 weeks after isolation 
of virus (231). Similar results were obtained in experimental 
coxsackievirus B3 infection (232) and in myocardial biopsies 
from patients with cardiomyopathy and myocarditis 
(233,234). Thus. the question of a pathogenetic role of 
persistent viral infection in subacute and chronic myocar- 
ditis must be reconsidered. 
Immunelautoimmune mechanisms. Experimental myo- 
carditis has been produced by immunization with myocardial 
proteins (235-238). The fact that trypanosomes can be dem- 
onstrated only rarely in subacute and chronic Chagas’ car- 
diomyopathy has led to the concept of chronic Chagas’ 
disease as an autoimmune disease, borne out by extensive 
clinical and experimental studies (239). Recent experimental 
studies (240) suggest that this form of auto-immune myocar- 
ditis is attributable to cross-reacting antigens of Trypano- 
soma cruzi and skeletal muscle, presumably mediated by 
cytotoxic T lymphocytes. Furthermore. an experimental 
myocarditis induced in mice by homologous heart immuni- 
zation has been shown to resemble chronic murine Chagas’ 
cardiomyopathy (241). 
Inasmuch as the isolation of cardiomyotropic viruses 
from myocardium only rarely is possible later than 2 weeks 
under inoculation or infection, subacute and chronic myo- 
carditis, as well as later noninflammatory cardiomyopathy, 
have also long been considered of immune or autoimmune 
origin. A great deal of evidence has accumulated in favor of 
immunopathogenesis of myocarditis and its late sequel of 
cardiomyopathy, derived from studies of humans and exper- 
imental animals, and several monographs and reviews have 
been published recently (242-248). 
Humoral and cellular irnmunitx mechanisms. Both in 
humans and in experimental animals, there is evidence that 
either humoral or cellular immunity, or both. may play a role 
in expression of both acute and chronic effects of viral 
replication in the heart. Evidence to date indicates that many 
different mechanisms may be operative. that these involve 
cytotoxic T lymphocytes, suppressor T lymphocytes and 
natural killer (NK) cells, and that the mechanisms as well as 
the biologic effects may be a function of genetic background, 
type and strain of virus. age. gender, species and strain of 
the host as well as other modifying factors such as stress. 
That immune processes are involved even in the expression 
of acute myocarditis was first demonstrated by Woodruff 
and Woodruff (249). who found that depletion of T lympho- 
cytes in mice infected with coxsackievirus B3 significantly 
suppressed both cellular infiltration and necrosis in the 
myocardium. Since then. evidence has accumulated for a 
cytotoxic role of T helper cells (L3T4) and T cytolytici 
suppressor cells (Lyt 2+), and for a myocardial protective 
role by activated natural killer (NK) cells and suppressor T 
lymphocytes (247.250). Evidence has also been presented 
for deficient natural killer cell activity in patients with dilated 
cardiomyopathy (25 1.252). 
Degeneration of cardiac ganglia. The well known dysau- 
tonomia associated with degeneration and loss of cardiac 
ganglia in Chagas’ disease led Amorim and Olsen (253) to 
study seven hearts from patients with dilated cardiomyopa- 
thy. They found a significant loss of ganglion cells in the 
sino-atrial region, whereas collagen tissue was increased. 
Neither the cause of this neuronal degeneration nor its 
functional significance is known, nor is it clear whether this 
is a primary or a secondary phenomenon or even an epiphe- 
nomenon. 
Alterations in the cardiac cytoskeleton. Noncontractile 
elements of the myocardium have been relatively neglected 
in the search for pathogenetic mechanisms in dilated cardio- 
myopathy. Yet. myocytes are surrounded by a network of 
bundles of collagen that are below the limits of resolution of 
light microscopy and best studied by means of scanning 
electron microscopy (254). Alterations of the collagen matrix 
have been observed in experimental cardiac hypertrophy 
(255) and also after a single injection of Adriamycin in rats 
(256). 
“interstitial heart disease. *’ A correlative study of histo- 
pathology and left ventricular function in 24 patients with 
dilated cardiomyopathy by Nakayama et al. (257) reported a 
relation of degree of impairment of ventricular function with 
proliferation of collagen fibers. More recently, studies of the 
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collagen matrix in three postmortem hearts from patients 
with dilated cardiomyopathy by Weber et al. (258) revealed 
evidence for pathologic remodeling of collagen, involving a 
shift from a stronger to a weaker type of collagen. The 
authors hypothesized that these changes may play a role in 
cardiac dilation and hence put forward the concept of 
“interstitial heart disease” and recommend the substitution 
of “cardiopathy” for “cardiomyopathy.” 
Diagnosis 
In view of the protean manifestations and initial presen- 
tations of dilated cardiomyopathy already mentioned, an 
awareness of its existence and prevalence is paramount for 
its detection. The failure to diagnose dilated cardiomyopathy 
is most frequently seen in the early stages of the disease in 
association with the custom of limiting cardiac diagnosis to 
labeling of manifestations, such as “cardiac arrhythmia” or 
“congestive heart failure,” and in the mislabeling of dilated 
cardiomyopathy as ischemic heart disease attributable in 
part to the latter’s high prevalence. Occasionally, insuffi- 
ciency of either or both AV valves may lead to a misdiag- 
nosis of valvular heart disease. In most cases, however, 
careful clinical evaluation and judicious use of noninvasive 
methods, such as echocardiography and radioventriculogra- 
phy, should lead to the correct diagnosis. 
Differentiation from coronary artery disease. There re- 
mains, however, a group of patients, especially men, with 
coronary risk factors, whose myocardial dysfunction is 
regional and who may give a history of typical or atypical 
angina1 chest pain. Here, coronary angiography is essential. 
It must also be kept in mind that three vessel coronary 
disease may be painless and associated with global hypoki- 
nesia of the left ventricle. Finally, there are patients with 
significant coronary atherosclerosis whose myocardial dys- 
function appears to be disproportionate to the degree of 
coronary disease. By definition, as long as significant coro- 
nary obstruction exists, these patients cannot be classified as 
having a cardiomyopathy. Yet, pathogenetically and patho- 
physiologically, a cardiomyopathic process may exist, and 
its recognition and identification of causal factors may be of 
value for purposes of prognosis, therapy and secondary 
prevention. Of special importance in this regard is the 
identification of chronic alcohol abuse. 
Therapy 
Inasmuch as true dilated cardiomyopathies are of un- 
known origin, treatment is symptomatic and nonspecific as 
contrasted with specific heart muscle diseases, for many of 
which specific therapy is available (5). Hence, it is necessary 
to evaluate every patient with dilated cardiomyopathy for 
the possible existence of a specific etiology that might 
identify a specific therapeutic approach. The therapeutic 
approach to decompensated dilated cardiomyopathy differs 
little from that to congestive heart failure in general and was 
reviewed in depth in a recent contribution by Parmley (259) 
to this Anniversary series of articles and also by Cohn (260). 
The discussion here will be limited to considerations of 
special relevance to dilated cardiomyopathy. 
Diuretics. In the use of diuretics, it should be kept in mind 
that loss of electrolytes and water-soluble vitamins may affect 
the structure and function of myocardium adversely, and that 
excessive volume depletion may result in depression of ven- 
tricular filling pressures below the optimal level, 
Vasodilators. Vasodilators represent the major advance 
in the therapy of dilated cardiomyopathy in recent years. 
Unlike ischemic heart disease, an arterial pressure signifi- 
cantly below normal may be acceptable in dilated cardiomy- 
opathy; thus, higher doses of vasodilators may be tolerated. 
However, the physician must be alert to possible deleterious 
effects on cerebral and renal function (261). Evidence for 
prolongation of life has been demonstrated for the combina- 
tion of hydralazine and isosorbide dinitrate (262) and for 
converting enzyme inhibitors (263). 
Digitalis and inotropic agents. Digitalis glycosides, albeit 
now recognized as relatively weak positive inotropic agents, 
are still of value in these patients (264,265). In cases of 
intractable, advanced congestive heart failure, hospitaliza- 
tion and a course of intravenous amrinone or dobutamine, 
under close supervision, may initiate diuresis and result in 
considerable symptomatic and objective improvement 
(266,267). Such a course may have to be repeated every few 
weeks. A sophisticated recent study of the physiologic 
mechanisms determining the hemodynamic response to do- 
butamine demonstrated significant differences in responses 
between a group with appropriate and another with inappro- 
priate hypertrophy, the latter exhibiting a significantly atten- 
uated response (268). 
Calcium channel blockers. The considerable evidence for 
a role of calcium overload and the preventive value of 
verapamil (see earlier) in several experimental forms of 
cardiomyopathy, as well as circumstantial evidence for a 
role of myocardial hypoxia, have led to a number of efforts 
to treat dilated cardiomyopathy with calcium antagonists, 
recently reviewed by Colucci (269). Evidence for negative 
inotropic effects of these agents has limited their clinical use 
in advanced dilated cardiomyopathy; controlled trials, espe- 
cially in the early stages, should be considered. 
Antiarrbythmic agents. High grade ventricular ectopic 
activity is frequent in dilated cardiomyopathy, generally 
correlating with the severity of systolic dysfunction and 
often responding to therapeutic improvement of ventricular 
function. Pharmacologic approaches to the management of 
arrhythmias in this setting have been discussed recently by 
Myerburg et al. (270). 
Beta-adrenergic blockers. Waagstein et al. (271) first re- 
ported beneficial effects of treatment of patients with dilated 
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cardiomyopathy and a high rest heart rate with beta- 
adrenergic blockade. This approach has its conceptual jus- 
tification inasmuch as it addresses the increased activity of 
the adrenergic nervous system in congestive heart failure, 
initially blocks the beta-adrenergic receptors and then per- 
mits up-regulation of the beta,-receptors down regulated by 
the chronic effects of norepinephrine (272). However, the 
negative inotropic effects of beta-blockade justifiably have 
been of concern. A number of uncontrolled studies 
(273,274), however, have suggested the value of this ap- 
proach. Until the results of controlled trials now in progress 
become available, clinical use of this mode of therapy best 
be restricted to patients with tachycardia and patients in 
relatively early stages of the disease. 
viewed with emphasis on recent developments and unsolved 
questions. 
Coenzyme Q,,,. Several studies have been reported of 
therapy of patients with dilated cardiomyopathy with coen- 
zyme Qlo, a redox coenzyme of several mitochondrial 
enzymes (275,276) that has been believed to be deficient in 
diseased hearts. Further study appears warranted. 
In the last 40 years, understanding of the diseases of heart 
muscle has advanced from clinical descriptions, first to 
pathophysiological understanding and, more recently, to 
gradual unveiling of likely pathogenetic mechanisms. The 
application of techniques of molecular biology and genetics 
is just beginning to bear fruit. Much of the progress has been 
facilitated by the development of experimental models of 
heart muscle disease, and we owe much to the contributions 
made by experimental animals. The use of isolated and 
cultured heart muscle ceils is still in its infancy, and better 
techniques for culturing adult myocytes are needed. A major 
difficulty encountered in research of human cardiomyopa- 
thies. and to a lesser extent of experimental cardiomyopa- 
thies, is the differentiation between primary, causal and 
secondary abnormalities in structure and function. Thus, 
greater emphasis must be placed on studying early, pre-heart 
failure stages of cardiomyopathy. 
Anticoagulants. In view of the high incidence of throm- 
boembolic complications, all patients with dilated cardiomy- 
opathy and chronic heart failure, unless there is a contrain- 
dication, should receive therapy with a coumarin derivative. 
This therapy has been validated (277). 
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